{"id":259953,"date":"2026-01-30T21:27:07","date_gmt":"2026-01-30T21:27:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/259953\/"},"modified":"2026-01-30T21:27:07","modified_gmt":"2026-01-30T21:27:07","slug":"fda-approves-subcutaneous-amivantamab-joelle-fathi-dnp-shares-key-nursing-implications","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/259953\/","title":{"rendered":"FDA Approves Subcutaneous Amivantamab: Joelle Fathi, DNP, Shares Key Nursing Implications"},"content":{"rendered":"

With the recent approval of subcutaneous amivantamab (Rybrevant Faspro) for certain patients with EGFR-mutated non\u2013small cell lung cancer (NSCLC), GO2 for Lung Cancer<\/a> Chief Healthcare Delivery Officer Joelle Fathi, DNP, RN, ARNP,\u00a0joined Cancer Nursing Today to discuss how the use of the subcutaneous formulation may affect patients, nurses, and healthcare systems overall.<\/p>\n

For example, there are multiple oncology nursing considerations surrounding the subcutaneous formulation, including reduced administration time and reduced administration-related reactions, Dr. Fathi said.<\/p>\n

\u201cFirst and foremost\u2014in thinking through the patients who are on the receiving end of this medication and what they have been through up to this point\u2014this medication offers an opportunity to regain some of their autonomy and their quality of life,\u201d Dr. Fathi said.<\/p>\n

In a press release<\/a>, Johnson & Johnson officials highlighted that the approval of the subcutaneous formulation is a \u201cpivotal step forward\u201d in treatment for patients with EGFR-mutated NSCLC and highlighted several key points related to the new formulation, including survival data from the phase 3 PALOMA-3 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024. The study showed that patients who received the subcutaneous formulation had a longer duration of response, increased progression-free survival, and increased overall survival compared with patients who received the IV formulation.<\/p>\n

\u201cThe subcutaneous formulation had a very favorable effectiveness and safety profile,\u201d Dr. Fathi said. \u201cThese things matter. That\u2019s what we\u2019re aiming for\u2014to get the most tolerable and effective treatment to the patients at the right time.\u201d Beyond the efficacy profile of the subcutaneous formulation, Dr. Fathi also highlighted safety data and practical considerations for oncology nurses and patients, including insights surrounding toxicities, such as venous thromboembolism.<\/p>\n

\u201cThe safety profile of [the subcutaneous formulation]\u00a0is of particular interest,\u201d Dr. Fathi said. \u201cIt\u2019s fascinating that there were significantly reduced administration-related reactions, not only in venous thromboembolic events, but also [in terms of] other toxicities that tend to come with chemotherapeutic agents. Any of these side effects are undesirable, but some can be more severe and fatal than others. We can\u2019t underestimate what this improved safety profile for this subcutaneous formulation means, not only for the patients, but [also] for the providers who are administering and ordering this medication.\u201d<\/p>\n

In addition to the safety and efficacy data, Dr. Fathi also explained the healthcare system\u2013level considerations surrounding the subcutaneous administration route as compared with the IV route.<\/p>\n

\u201cYou\u2019re not having to schedule a significant block of time for patients to come in, get settled, get an IV or have access established, and monitor them while they\u2019re getting their IV administration,\u201d Dr. Fathi said.<\/p>\n

Dr. Fathi concluded that the FDA approval of the subcutaneous formulation also reflects a broader evolution in the field of oncology.<\/p>\n

\u201cWe think about the comfort for the patients and the nurses on the side of healthcare delivery,\u201d Dr. Fathi said. \u201cBeing able to offer a subcutaneous formulation\u2014give people the medication and know that the chances that there\u2019s going to be an adverse event are less with the subcutaneous versus the IV version\u2014lessens the worry for nurses. It\u2019s exciting to imagine how this will transform the future of how we treat patients with advanced EGFR-mutated NSCLC.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"With the recent approval of subcutaneous amivantamab (Rybrevant Faspro) for certain patients with EGFR-mutated non\u2013small cell lung cancer…\n","protected":false},"author":2,"featured_media":259954,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[111,139,69,145],"class_list":{"0":"post-259953","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-technology","8":"tag-new-zealand","9":"tag-newzealand","10":"tag-nz","11":"tag-technology"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/259953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=259953"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/259953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/259954"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=259953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=259953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=259953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}